What is Bio Medica Laboratories IPO GMP Today?
The Latest GMP of Bio Medica Laboratories Ltd IPO is ₹0.
Bio Medica Laboratories IPO GMP
| DATE | GMP (GREY MARKET PREMIUM) | EXPECTED LISTING GAINS |
|---|---|---|
| 25-May-2026 | – | – |
| 24-May-2026 | – | – |
| 23-May-2026 | – | – |
| 22-May-2026 | – | – |
| 21-May-2026 | – | – |
IPO Grey Market Premium (GMP) – bio medica laboratories ipo gmp
The grey market premium (GMP) represents the informal trading price in grey market of an IPO before it officially lists on the stock exchange. The GMP can provide an early snapshot of investor sentiment and the expected demand for shares once they are listed. A higher GMP generally suggests positive market expectations, while a lower or negative GMP may indicate cautious sentiment.
It is important to remember that GMP values are purely indicative and can change rapidly due to short-term market factors, speculative trading, or investor perception. They do not guarantee how the IPO will perform on the listing day.
Investors should not base their investment decision solely on GMP. Instead, a careful analysis of the company’s business model, financial health, industry position, and growth potential should guide the decision to participate in the IPO. Using GMP as one of many reference points can help, but relying on it alone carries significant risk.
Bio Medica Laboratories IPO: GMP, Key Dates, Price, and In-depth Review
The contract development and manufacturing organization (CDMO) segment within the Indian pharmaceutical ecosystem is expanding rapidly. Joining this growth curve is Bio Medica Laboratories Limited, which has floated its public offer to fund capital-intensive manufacturing expansions. The Bio Medica Laboratories IPO opens for registration on May 21, 2026, targeting investors keen on entering the core pharmaceutical parenteral formulations domain.
Company Overview: Who is Bio Medica Laboratories Ltd?
Incorporated in August 2015, Bio Medica Laboratories Limited specializes in the contract manufacturing of pharmaceutical parenteral formulations. The company designs, develops, and produces liquid and dry-powder injectables in single-dose and multi-dose configurations for both human healthcare networks and the veterinary medical ecosystem.
Bio Medica Laboratories IPO Key Facts & Timeline
The issue utilizes a book-built mechanism, offering equity space on the NSE SME network.
Crucial Timetable Dates
- IPO Opening Date: May 21, 2026
- IPO Closing Date: May 25, 2026
- Basis of Allotment Date: May 26, 2026
- Initiation of Refunds: May 27, 2026
- Credit of Shares to Demat Accounts: May 27, 2026
- Tentative Listing Date: May 29, 2026
Pricing and Volume Architecture
- Face Value: ₹10 per equity share
- Price Band: ₹132 to ₹139 per share
- Total Issue Size: 37,72,000 equity shares (aggregating to ₹52.43 Crore)
- Fresh Issue Component: ₹47.19 Crore (34,00,000 shares)
- Offer for Sale (OFS): ₹5.24 Crore (3,72,000 shares)
- Market Lot Size: 1,000 shares per lot
Required Bid Allocations
Financial Review & Business Metrics
The financial statements of Bio Medica Laboratories show a business model capitalizating on bulk pharmaceutical orders:
- Asset Scale-up: The total assets have seen regular expansion, supporting the setting up of sterile dry-powder formulation labs.
- Revenue Streams: Growth in total turnover shows that contract renewals with existing pharmaceutical labels have remained stable.
- Balanced Leverage: Although the company holds short-term debt taken to purchase initial factory machinery, its debt-servicing ratios stay safely within corporate limits.
Core Strengths and Potential Risks
Primary Strengths:
- Dual-Market Capabilities: Manufacturing both human-use and veterinary-grade injectables provides solid revenue diversification.
- Strict Quality Clearances: Maintaining audited GLP and GMP facilities reduces the threat of surprise plant suspensions by health inspectors.
- High Entry Barriers: Injectable formulation lines require strict environment controls, protecting the company from sudden new competitors.
Core Operational Risks:
- Concentrated Client Base: Operating primarily as a B2B contract manufacturer means losing a single major pharmaceutical client could hit annual revenues hard.
- Raw Material Price Swings: Variations in the price of Active Pharmaceutical Ingredients (APIs) can pressure operational margins if contract prices cannot be adjusted quickly.
Objectives of the Public Issue
The gross capital raised via this offering will be deployed to achieve the following:
- Capacity Expansion: Allocating ₹28.50 Crore to construct an upgraded manufacturing facility within current premises.
- Deleveraging: Utilizing ₹6.50 Crore to repay existing institutional loans to improve financial ratios.
- Funding general corporate milestones and primary issue overheads.